CBSC (Cardiac Biotech Solutions) Other Income (Expense): $0.44 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Other Income (Expense)?

Cardiac Biotech Solutions CBSC Other Income (Expense) is $0.44 Mil as of Jun. 2026.

Cardiac Biotech Solutions's other income expense for the Cardiac Biotech Solutions's pretax income for the three months ended in Jun. 2026 was $0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Jun. 2026 was $0.44 Mil.

Cardiac Biotech Solutions  (OTCPK:CBSC) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Cardiac Biotech Solutions Other Income (Expense) Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Other Income (Expense) Chart

Cardiac Biotech Solutions Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.93 0.00 -0.03 -0.10 0.51

Cardiac Biotech Solutions Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.42 0.00 0.03 0.00

Cardiac Biotech Solutions Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Income (Expense) →
What does a Other Income (Expense) of $0.44 Mil mean?
Cardiac Biotech Solutions (CBSC) has a Other Income (Expense) of $0.44 Mil as of Jun. 2026. Other income and expenses that a company records on the income statement. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Other Income (Expense) too high?
Cardiac Biotech Solutions' current Other Income (Expense) is $0.44 Mil.
How does Cardiac Biotech Solutions' Other Income (Expense) compare to LUCY and NXGL?
Cardiac Biotech Solutions' Other Income (Expense) of $0.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Income (Expense) for a Medical Devices & Instruments company?
A good Other Income (Expense) depends on the Medical Devices & Instruments industry context. However, Other Income (Expense) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Income (Expense) mean?
A high Other Income (Expense) can signal that a stock is expensive relative to its fundamentals. Other income and expenses that a company records on the income statement. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Other Income (Expense) is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Other Income (Expense) of $0.44 Mil. The current Other Income (Expense) is $0.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Income (Expense) calculated?
Other Income (Expense) is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Other Income (Expense) is $0.44 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.